** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences (Nanjing) Inc 2617.HK climb 3% to HK$173

** Stock on course to end the week up 5.9%, snapping three straight weekly losess

** TransThera said new drug application for its Tinengotinib tablets for treatment of metastatic cholangiocarcinoma in adults has been accepted by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA)

** There is no assurance that the relevant product will ultimately be successfully developed and marketed - Co

** Stock, which debuted on June 23, up 1,190% so far from the offer price of HK$13.15 apiece

** YTD, Hang Seng Biotech index .HSBIO up 74.3%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))